Phase II single arm study of durvalumab and olaparib (D plus O) in heavily pretreated triple-negative breast cancer (TNBC) with or without germline BRCA mutation (gBRCAm)

被引：0
|
作者：
Fujii, T. [1 ]
Lipkowitz, S. [1 ]
Zimmer, A. D. S. [1 ]
Villanueva, E. [1 ]
Solarz, B. B. [1 ]
Lee, J-M. [1 ]
机构：
[1] Natl Canc Insitute, Womens Malignancies Branch, Ctr Canc Res, Bethesda, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.611
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
435P
引用
收藏
页码：S364 / S364
页数：1
相关论文
共 50 条
  • [21] Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).
    Sharma, Priyanka
    Stecklein, Shane Richard
    Yoder, Rachel
    Staley, Joshua M.
    Schwensen, Kelsey
    O'Dea, Anne
    Nye, Lauren Elizabeth
    Elia, Manana
    Satelli, Deepti
    Crane, Gregory
    Madan, Rashna
    O'Neil, Maura F.
    Wagner, Jamie L.
    Larson, Kelsey E.
    Balanoff, Christa
    Phadnis, Milind A.
    Godwin, Andrew K.
    Salgado, Roberto
    Khan, Qamar J.
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
    Jieqiong Liu
    Ying Wang
    Zhenluan Tian
    Ying Lin
    Hengyu Li
    Zhaowen Zhu
    Qiang Liu
    Shicheng Su
    Yinduo Zeng
    Weijuan Jia
    Yaping Yang
    Shengqiang Xu
    Herui Yao
    Wen Jiang
    Erwei Song
    Nature Communications, 13
  • [23] Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
    Liu, Jieqiong
    Wang, Ying
    Tian, Zhenluan
    Lin, Ying
    Li, Hengyu
    Zhu, Zhaowen
    Liu, Qiang
    Su, Shicheng
    Zeng, Yinduo
    Jia, Weijuan
    Yang, Yaping
    Xu, Shengqiang
    Yao, Herui
    Jiang, Wen
    Song, Erwei
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [24] Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
    Drew, Y.
    Penson, R. T.
    O'Malley, D. M.
    Kim, J-W.
    Zimmermann, S.
    Roxburgh, P.
    Sohn, J.
    Stemmer, S. M.
    Bastian, S.
    Ferguson, M.
    You, B.
    Domchek, S.
    Gao, H.
    Angell, H.
    Meyer, K.
    Opincar, L.
    Ottesen, L.
    Koralek, D. O.
    Banerjee, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S615 - S616
  • [25] Combination ipatasertib and atezolizumab to prevent recurrence in triple negative breast cancer(TNBC): A phase II single arm trial
    Mittendorf, Elizabeth
    Tolaney, Sara
    Wileyto, Paul
    Demeo, Michelle
    Rugo, Hope
    Nanda, Rita
    Mayer, Ingrid
    Park, Ben
    MacArthur, Heather
    DeMichelle, Angela
    CANCER RESEARCH, 2021, 81 (04)
  • [26] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine M.
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten Dietrich
    Runswick, Sarah
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [27] A randomized phase II study of nab-paclitaxel plus durvalumab plus neoantigen vaccine versus nab-paclitaxel plus durvalumab in metastatic triple-negative breast cancer (mTNBC).
    Hernandez-Aya, Leonel Fernando
    Gao, Feng
    Goedegebuure, Peter S.
    Ma, Cynthia X.
    Ademuyiwa, Foluso Olabisi
    Park, Haeseong
    Peterson, Lindsay Leuthen
    Bagegni, Nusayba Ali
    Bose, Ron
    Gillanders, William E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine M.
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten Dietrich
    Runswick, Sarah
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] NeoBREASTIM: A phase II study of atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting of triple-negative breast cancer (TNBC)
    Bastien, E.
    Grandal, B.
    Sanchez, R.
    Ramtohul, T.
    Loirat, D.
    Sablin, M. P.
    Vincent-Salomon, A.
    Pierga, J-Y.
    Bidard, F. C.
    Malhaire, C.
    Savignoni, A.
    Romano, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S347 - S348
  • [30] Single arm study of neoadjuvant chemotherapy without taxane for BRCAness cases in triple-negative breast cancer
    Ishikawa, Takashi
    Teraoka, Saeko
    Kaise, Hiroshi
    Yamada, Kimito
    Hosonaga, Man
    Ueda, Ai
    Kawai, Yoko
    Okazaki, Miki
    Oba, Mari S.
    Sato, Eiichi
    CANCER RESEARCH, 2016, 76
12345